title: Coverage by the news media of the benefits and risks of medications.
abstract: BACKGROUND
  The news media are an important source of information about new medical treatments, but there is concern that some coverage may be inaccurate and overly enthusiastic.
  
  
  METHODS
  We studied coverage by U.S. news media of the benefits and risks of three medications that are used to prevent major diseases. The medications were pravastatin, a cholesterol-lowering drug for the prevention of cardiovascular disease; alendronate, a bisphosphonate for the treatment and prevention of osteoporosis; and aspirin, which is used for the prevention of cardiovascular disease. We analyzed a systematic probability sample of 180 newspaper articles (60 for each drug) and 27 television reports that appeared between 1994 and 1998.
  
  
  RESULTS
  Of the 207 stories, 83 (40 percent) did not report benefits quantitatively. Of the 124 that did, 103 (83 percent) reported relative benefits only, 3 (2 percent) absolute benefits only, and 18 (15 percent) both absolute and relative benefits. Of the 207 stories, 98 (47 percent) mentioned potential harm to patients, and only 63 (30 percent) mentioned costs. Of the 170 stories citing an expert or a scientific study, 85 (50 percent) cited at least one expert or study with a financial tie to a manufacturer of the drug that had been disclosed in the scientific literature. These ties were disclosed in only 33 (39 percent) of the 85 stories.
  
  
  CONCLUSIONS
  News-media stories about medications may include inadequate or incomplete information about the benefits, risks, and costs of the drugs as well as the financial ties between study groups or experts and pharmaceutical manufacturers.
authors.affiliation: Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA.
authors.forename: R
authors.initials: R
authors.lastname: Moynihan
authors.forename: L
authors.initials: L
authors.lastname: Bero
authors.forename: D
authors.initials: D
authors.lastname: Ross-Degnan
authors.forename: D
authors.initials: D
authors.lastname: Henry
authors.forename: K
authors.initials: K
authors.lastname: Lee
authors.forename: J
authors.initials: J
authors.lastname: Watkins
authors.forename: C
authors.initials: C
authors.lastname: Mah
authors.forename: S B
authors.initials: SB
authors.lastname: Soumerai
mesh_terms: D019386:Alendronate / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D035843:Biomedical Research; D002318:Cardiovascular Diseases / Q000517:prevention & control; D016265:Conflict of Interest; D003362:Cost-Benefit Analysis; D030881:Disclosure; D004358:Drug Therapy / Q000191:economics; D064420:Drug-Related Side Effects and Adverse Reactions; D005252:Fees, Pharmaceutical; D006801:Humans; D018156:Journalism, Medical; D008402:Mass Media / Q000706:statistics & numerical data; D009524:Newspapers as Topic; D010024:Osteoporosis / Q000517:prevention & control; D017035:Pravastatin / Q000627:therapeutic use; D018570:Risk Assessment; D013690:Television; D014481:United States
chemical_list: D000924:Anticholesteremic Agents; D017035:Pravastatin; D001241:Aspirin; D019386:Alendronate